(Q53827413)

English

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

type 2 diabetes

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

K Kaku

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Katou

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T Ohira

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

H Sano

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

23 October 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1198-1201

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12555

21 January 2018

Identifiers

10.1111/DOM.12555

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26277887%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53827413&oldid=1120764465"